Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD

0.7128  -0.01 (-1.61%)

Fundamental Rating

2

Taking everything into account, LXRX scores 2 out of 10 in our fundamental rating. LXRX was compared to 566 industry peers in the Biotechnology industry. Both the profitability and financial health of LXRX have multiple concerns. While showing a medium growth rate, LXRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LXRX had negative earnings in the past year.
In the past year LXRX has reported a negative cash flow from operations.
LXRX had negative earnings in each of the past 5 years.
In the past 5 years LXRX always reported negative operating cash flow.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

With a Return On Assets value of -67.15%, LXRX is not doing good in the industry: 63.78% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -137.31%, LXRX is doing worse than 61.84% of the companies in the same industry.
Industry RankSector Rank
ROA -67.15%
ROE -137.31%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

LXRX has a Gross Margin of 98.02%. This is amongst the best in the industry. LXRX outperforms 96.82% of its industry peers.
In the last couple of years the Gross Margin of LXRX has remained more or less at the same level.
LXRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
LXRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LXRX has more shares outstanding
LXRX has a better debt/assets ratio than last year.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

LXRX has an Altman-Z score of -9.46. This is a bad value and indicates that LXRX is not financially healthy and even has some risk of bankruptcy.
LXRX's Altman-Z score of -9.46 is on the low side compared to the rest of the industry. LXRX is outperformed by 73.32% of its industry peers.
LXRX has a Debt/Equity ratio of 0.69. This is a neutral value indicating LXRX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.69, LXRX is not doing good in the industry: 76.50% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Altman-Z -9.46
ROIC/WACCN/A
WACC11.25%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

LXRX has a Current Ratio of 5.44. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.44, LXRX is in line with its industry, outperforming 59.36% of the companies in the same industry.
LXRX has a Quick Ratio of 5.44. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Quick ratio of 5.44. This is comparable to the rest of the industry: LXRX outperforms 59.89% of its industry peers.
Industry RankSector Rank
Current Ratio 5.44
Quick Ratio 5.44
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

LXRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite good.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 2485.77%.
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)2485.77%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%3682.62%

3.2 Future

LXRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.99% yearly.
The Revenue is expected to grow by 75.28% on average over the next years. This is a very strong growth
EPS Next Y40.07%
EPS Next 2Y21.25%
EPS Next 3Y15.43%
EPS Next 5Y16.99%
Revenue Next Year-6.11%
Revenue Next 2Y31.71%
Revenue Next 3Y71.07%
Revenue Next 5Y75.28%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as LXRX's earnings are expected to grow with 15.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.25%
EPS Next 3Y15.43%

More info and screens

0

5. Dividend

5.1 Amount

LXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (5/2/2025, 10:50:37 AM)

0.7128

-0.01 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners84.5%
Inst Owner Change0.04%
Ins Owners0.74%
Ins Owner Change0.25%
Market Cap258.87M
Analysts80
Price Target2.65 (271.77%)
Short Float %11.58%
Short Ratio2.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.71%
Min EPS beat(2)-7.28%
Max EPS beat(2)30.7%
EPS beat(4)3
Avg EPS beat(4)8.95%
Min EPS beat(4)-7.28%
Max EPS beat(4)30.7%
EPS beat(8)6
Avg EPS beat(8)4.16%
EPS beat(12)9
Avg EPS beat(12)2.48%
EPS beat(16)13
Avg EPS beat(16)4.79%
Revenue beat(2)1
Avg Revenue beat(2)130.15%
Min Revenue beat(2)-41.43%
Max Revenue beat(2)301.73%
Revenue beat(4)1
Avg Revenue beat(4)49.1%
Min Revenue beat(4)-42.95%
Max Revenue beat(4)301.73%
Revenue beat(8)2
Avg Revenue beat(8)49.54%
Revenue beat(12)2
Avg Revenue beat(12)-0.31%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.78%
PT rev (3m)-27.78%
EPS NQ rev (1m)4%
EPS NQ rev (3m)23.2%
EPS NY rev (1m)1.7%
EPS NY rev (3m)18.76%
Revenue NQ rev (1m)13.28%
Revenue NQ rev (3m)-56.33%
Revenue NY rev (1m)-21.62%
Revenue NY rev (3m)-21.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.33
P/FCF N/A
P/OCF N/A
P/B 1.77
P/tB 2.55
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.09
BVpS0.4
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.15%
ROE -137.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.02%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 193.07%
Cap/Sales 3.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.44
Quick Ratio 5.44
Altman-Z -9.46
F-Score5
WACC11.25%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y40.07%
EPS Next 2Y21.25%
EPS Next 3Y15.43%
EPS Next 5Y16.99%
Revenue 1Y (TTM)2485.77%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%3682.62%
Revenue Next Year-6.11%
Revenue Next 2Y31.71%
Revenue Next 3Y71.07%
Revenue Next 5Y75.28%
EBIT growth 1Y-14.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.43%
OCF growth 3YN/A
OCF growth 5YN/A